The Psilocybin vs. Escitalopram Trial – Part 2

A deep dive into the strengths and limitations of the trial.

-

Part 1 focused on the study design and what the results revealed. However, a clinical trial of this significance warrants a further discussion of its limitations and strengths.

Limitations

Trial Duration

An adequate trial of escitalopram is typically 6-12 weeks, but there is quality evidence to suggest that approximately one-third of patients don’t fully respond to antidepressants until after six weeks of use.1,2 The current trial length of six weeks, therefore, may not have completely captured escitalopram’s efficacy.3

Blinding

The inability to successfully conceal which treatment group a participant is allocated to is a frequent criticism of all psychedelic research.4 Given how noticeable the subjective drug effects are, participants and study staff can easily guess which treatment is provided, and potentially influence the results. Unfortunately, this trial did not attempt to assess the unblinding of participants or study staff. There were at least two instances of patients successfully guessing their treatment referenced in the paper, and it could feasibly have happened at a high rate throughout the trial.  

Trial Population

A large enough sample required to detect a significant difference in efficacy was lacking in this trial (though normal for a Phase II trial) and is partly responsible for the inconclusive results. Additionally, the absence of diversity among participants (88% white, 66% male, and 76% university-educated), an ongoing problem in psychedelic and biomedical research overall, makes it challenging to generalize the results to a wider population of people suffering from depression.5,6

Impact of the Therapy?

An additional experimental group consisting of a placebo instead of escitalopram, with two sessions of 1 mg psilocybin and the same amount of therapy would be valuable to assess the impact of therapy alone and help tease out psilocybin’s true effects. This was part of the original protocol but was changed to avoid even smaller group numbers.

Strengths

Design

The trial is the most methodologically sound assessment of psilocybin’s efficacy in a population with major depressive disorder yet. This is largely due to the comparison with the most effective intervention available for treating depression, the combination of a first-line antidepressant and psychotherapy.7 Additionally, an intention-to-treat analysis was utilized, meaning the authors included all participants in their final calculations. The result is a more realistic estimate of the treatment’s efficacy and safety because it includes participants who may have dropped out early or did not adhere to the prescribed therapy, which occurred in small amounts in both groups.

Safety

The study adds to the growing body of evidence that psilocybin is quite safe and provides a direct comparison with a selective serotonin reuptake inhibitor (SSRI).8 While the overall side effect rates were comparable in the study, psilocybin may represent a safer option than SSRIs in part because only a small number of doses are administered and long-term side effects appear to be limited.9 Conversely, SSRIs are taken daily for extended periods, with the possibility of bothersome side effects continuing throughout and withdrawal symptoms following discontinuation.

It is important to note that the trial exclusion criteria and psychological support throughout functions to mitigate psilocybin’s risk.10 The participants are being reassessed after six months, which may reveal some differences in safety and any potential enduring effects.

Blunted Effects?

All participants were required to taper off and discontinue any antidepressants two weeks before the study start. Previous research points to marked attenuation of a similar psychedelic’s subjective effects in patients on chronic antidepressant therapy.11 Neural changes that occur with chronic antidepressant use are thought to be responsible and it is unclear if two weeks is sufficient for reversing them. Combined with the accumulating evidence that aspects of the subjective experience are correlated with the therapeutic effects, it is possible that the 11/30 psilocybin group participants required to discontinue an antidepressant may have experienced a reduced treatment response.12 COMPASS Pathways is conducting a trial to evaluate psilocybin’s antidepressant effects in participants currently taking an SSRI to determine whether they can be taken together or if psilocybin is more appropriate as a standalone treatment.13

Dosing Insights

It remains unclear how many psilocybin doses and at what frequency would best optimize the treatment’s safety and efficacy. The trial hinted that most of the benefits in the psilocybin group followed a single psilocybin session, which is the dosing regimen under exploration by the Usona Institute and others.14 The psilocybin group had Quick Inventory of Depressive Symptomatology (QIDS) score decreases of 5.7 and 6.9 points one day and one week after the first dose, respectively – both of which were significantly different from the escitalopram group and represent a large proportion of the total 8 point decrease that occurred over the six-week trial.

Like ketamine, psilocybin’s potential rapid antidepressant effect is a theoretical advantage over conventional antidepressants that have a delayed treatment response, particularly for patients with depression and suicidal ideation.15 That population has been mostly excluded from modern psilocybin research thus far but surely warrants further exploration in light of these results and other converging evidence of an anti-suicidal effect.16-18

Final Considerations

If not for the selection of the QIDS-SR-16 as the pre-registered primary outcome, the interpretation of this study might be more positive. The main author stated it was “a largely arbitrary choice”19, with possible influences from its previously successful use in this trial’s predecessor study,18 as well as its widespread acceptance by drug regulatory authorities. Some of the depression scales that were used as secondary outcomes may be more appropriate for future trials. Other currently pre-registered studies evaluating the antidepressant effects of psilocybin-assisted therapy utilize one of two clinician-rated scales, the Montgomery and Asberg Depression Rating Scale (MADRS) or the Hamilton Rating Scale for Depression (HAM-D).13,14,20-23

The study conducted by Dr. Robin Carhart-Harris and his colleagues is surely a landmark trial within psychedelic science, but one that raises more questions than answers. Larger Phase II studies currently underway and subsequent Phase III trials will provide more clarity about where psilocybin-assisted therapy stands as a potential antidepressant intervention.14,22,23

Comments

1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Floris Blossom
42 minutes ago

Thank you for the great breakdown Michael! Really good points about the strengths and weaknesses!

    References
  1. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments [published correction appears in Can J Psychiatry. 2017 May;62(5):356]. Can J Psychiatry. 2016;61(9):540-560. doi:10.1177/0706743716659417
  2. Rush AJ. STAR*D: what have we learned?. Am J Psychiatry. 2007;164(2):201-204. doi:10.1176/ajp.2007.164.2.201
  3. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994
  4. Muthukumaraswamy S, Forsyth A, Lumley T. Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials. Preprint. Posted online March 8, 2021. PsyArXiv. doi:10.31234/osf.io/q2hzm
  5. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245. Published 2018 Jul 31. doi:10.1186/s12888-018-1824-6
  6. Oh SS, Galanter J, Thakur N, et al. Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled. PLoS Med. 2015;12(12):e1001918. Published 2015 Dec 15. doi:10.1371/journal.pmed.1001918
  7. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56-67. doi:10.1002/wps.20089
  8. Thomas K, Malcolm B. Chapter 22: Adverse Effects. In: Grob CS, Grigsby J, eds. Handbook of Medical Hallucinogens. New York: The Guilford Press; 2021.
  9. Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. Neurosci Biobehav Rev. 2020;113:179-189. doi:10.1016/j.neubiorev.2020.03.017
  10. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620. doi:10.1177/0269881108093587
  11. Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 1996;14(6):425-436. doi:10.1016/0893-133X(95)00145-4
  12. Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci. 2020;4(2):568-572. Published 2020 Dec 10. doi:10.1021/acsptsci.0c00194
  13. The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants with Treatment Resistant Depression. ClinicalTrials.gov identifier: NCT04739865. Accessed April 26, 2021. https://clinicaltrials.gov/ct2/show/NCT04739865
  14. A Study of Psilocybin for Major Depressive Disorder (MDD). ClinicalTrials.gov identifier: NCT03866174. Accessed April 17, 2021. https://clinicaltrials.gov/ct2/show/NCT03866174
  15. Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150-158. doi:10.1176/appi.ajp.2017.17040472
  16. Ross S, Agin-Liebes G, Lo S, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci. 2021;4(2):553-562. Published 2021 Mar 18. doi:10.1021/acsptsci.1c00020
  17. Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280-288. doi:10.1177/0269881114565653
  18. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7
  19. Carhart-Harris R. Data vs spin: commentary on “Trial of Psilocybin versus Escitalopram for Depression”. MyDelica Blog. Posted April 14, 2021. Accessed April 26, 2021. https://mydelica.com/blog/data-vs-spin.html
  20. The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density (PSIPET). ClinicalTrials.gov identifier: NCT04630
  21. An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD). Clinicaltrials.gov identifier: NCT04433858. Accessed April 26, 2021.
  22. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression (EPIsoDE). ClinicalTrials.gov identifier: NCT04670081. Accessed April 26, 2021. https://clinicaltrials.gov/ct2/show/NCT04670081
  23. The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD). ClinicalTrials.gov identifier: NCT03775200. Accessed April 26, 2021. https://clinicaltrials.gov/ct2/show/NCT03775200